U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H7NO3
Molecular Weight 153.1357
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MESALAMINE

SMILES

c1cc(c(cc1N)C(=O)O)O

InChI

InChIKey=KBOPZPXVLCULAV-UHFFFAOYSA-N
InChI=1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)

HIDE SMILES / InChI

Molecular Formula C7H7NO3
Molecular Weight 153.1357
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: https://www.drugs.com/mtm/mesalamine.html

Mesalamine, also known as Mesalazine or 5-aminosalicylic acid (5-ASA), is an anti-inflammatory drug used to treat inflammation of the digestive tract (Crohn's disease) and mild to moderate ulcerative colitis. Mesalazine is a bowel-specific aminosalicylate drug that is metabolized in the gut and has its predominant actions there, thereby having fewer systemic side effects. As a derivative of salicylic acid, 5-ASA is also an antioxidant that traps free radicals, which are potentially damaging by-products of metabolism. Although the mechanism of action of mesalazine is not fully understood, it appears to be topical rather than systemic. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes and hydroxyeicosatetraenoic acids, is increased in patients with chronic inflammatory bowel disease, and it is possible that mesalazine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon. Mesalazine is used for the treatment of active ulcerative proctitis.

CNS Activity

Curator's Comment:: Mesalazine and acetyl mesalazine do not cross the blood brain barrier.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PENTASA

Approved Use

PENTASA is indicated for the induction of remission and for the treatment of patients with mildly to moderately active ulcerative colitis.

Launch Date

736905600000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
150 ng/mL
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MESALAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
1595 ng/mL
2.4 g single, oral
dose: 2.4 g
route of administration: Oral
experiment type: SINGLE
co-administered:
MESALAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
2154 ng/mL
4.8 g single, oral
dose: 4.8 g
route of administration: Oral
experiment type: SINGLE
co-administered:
MESALAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
857 ng/mL
1.2 g single, oral
dose: 1.2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
MESALAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
909 ng × h/mL
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MESALAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
21084 ng × h/mL
2.4 g single, oral
dose: 2.4 g
route of administration: Oral
experiment type: SINGLE
co-administered:
MESALAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
44775 ng × h/mL
4.8 g single, oral
dose: 4.8 g
route of administration: Oral
experiment type: SINGLE
co-administered:
MESALAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
9578 ng × h/mL
1.2 g single, oral
dose: 1.2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
MESALAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
25 h
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MESALAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
7.05 h
2.4 g single, oral
dose: 2.4 g
route of administration: Oral
experiment type: SINGLE
co-administered:
MESALAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
7.25 h
4.8 g single, oral
dose: 4.8 g
route of administration: Oral
experiment type: SINGLE
co-administered:
MESALAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
8.56 h
1.2 g single, oral
dose: 1.2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
MESALAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
57%
1.2 g single, oral
dose: 1.2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
MESALAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
14.5 g single, oral|rectal
Overdose
Dose: 14.5 g
Route: oral|rectal
Route: single
Dose: 14.5 g
Sources:
unhealthy, 20 - years
Health Status: unhealthy
Age Group: 20 - years
Sex: M
Sources:
Disc. AE: Intoxication...
AEs leading to
discontinuation/dose reduction:
Intoxication (1 patient)
Sources:
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, 28 - 41 years
Health Status: unhealthy
Age Group: 28 - 41 years
Sex: F
Sources:
15.7 mg/kg 1 times / day steady, oral (mother), breasteeding (infant)
Dose: 15.7 mg/kg, 1 times / day
Route: oral (mother), breasteeding (infant)
Route: steady
Dose: 15.7 mg/kg, 1 times / day
Sources:
healthy, 35–251 days
Health Status: healthy
Age Group: 35–251 days
Sex: M+F
Sources:
3.2 g 1 times / day steady, oral
Recommended
Dose: 3.2 g, 1 times / day
Route: oral
Route: steady
Dose: 3.2 g, 1 times / day
Sources:
unhealthy, 42 years
Health Status: unhealthy
Age Group: 42 years
Sex: M
Sources:
Disc. AE: Hypersensitivity...
AEs leading to
discontinuation/dose reduction:
Hypersensitivity (1 patient)
Sources:
1.6 g 1 times / day steady, oral
Recommended
Dose: 1.6 g, 1 times / day
Route: oral
Route: steady
Dose: 1.6 g, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Disc. AE: Anxiety, Headache...
AEs leading to
discontinuation/dose reduction:
Anxiety (1 patient)
Headache (1 patient)
Pruritus (1 patient)
Libido decreased (1 patient)
Rheumatoid arthritis (1 patient)
Asthenia (1 patient)
Sources:
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Disc. AE: Diarrhea, Colitis...
AEs leading to
discontinuation/dose reduction:
Diarrhea (1 patient)
Colitis (1 patient)
Dizziness (1 patient)
Nausea (1 patient)
Joint pain (1 patient)
Headache (2 patients)
Rash (1 patient)
Lethargy (1 patient)
Constipation (1 patient)
Dry mouth (1 patient)
Malaise (1 patient)
Back discomfort (1 patient)
Disorientation (1 patient)
Indigestion (1 patient)
Nausea (1 patient)
Generalised aching (1 patient)
Vomiting (1 patient)
Muscle cramps (1 patient)
Nasal congestion (1 patient)
Eustachian tube obstruction (1 patient)
Fever (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Intoxication 1 patient
Disc. AE
14.5 g single, oral|rectal
Overdose
Dose: 14.5 g
Route: oral|rectal
Route: single
Dose: 14.5 g
Sources:
unhealthy, 20 - years
Health Status: unhealthy
Age Group: 20 - years
Sex: M
Sources:
Hypersensitivity 1 patient
Disc. AE
3.2 g 1 times / day steady, oral
Recommended
Dose: 3.2 g, 1 times / day
Route: oral
Route: steady
Dose: 3.2 g, 1 times / day
Sources:
unhealthy, 42 years
Health Status: unhealthy
Age Group: 42 years
Sex: M
Sources:
Anxiety 1 patient
Disc. AE
1.6 g 1 times / day steady, oral
Recommended
Dose: 1.6 g, 1 times / day
Route: oral
Route: steady
Dose: 1.6 g, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Asthenia 1 patient
Disc. AE
1.6 g 1 times / day steady, oral
Recommended
Dose: 1.6 g, 1 times / day
Route: oral
Route: steady
Dose: 1.6 g, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Headache 1 patient
Disc. AE
1.6 g 1 times / day steady, oral
Recommended
Dose: 1.6 g, 1 times / day
Route: oral
Route: steady
Dose: 1.6 g, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Libido decreased 1 patient
Disc. AE
1.6 g 1 times / day steady, oral
Recommended
Dose: 1.6 g, 1 times / day
Route: oral
Route: steady
Dose: 1.6 g, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Pruritus 1 patient
Disc. AE
1.6 g 1 times / day steady, oral
Recommended
Dose: 1.6 g, 1 times / day
Route: oral
Route: steady
Dose: 1.6 g, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Rheumatoid arthritis 1 patient
Disc. AE
1.6 g 1 times / day steady, oral
Recommended
Dose: 1.6 g, 1 times / day
Route: oral
Route: steady
Dose: 1.6 g, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Back discomfort 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Colitis 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Constipation 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Diarrhea 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Disorientation 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Dizziness 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Dry mouth 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Eustachian tube obstruction 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Fever 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Generalised aching 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Indigestion 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Joint pain 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Lethargy 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Malaise 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Muscle cramps 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Nasal congestion 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Nausea 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Nausea 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Rash 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Vomiting 1 patient
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Headache 2 patients
Disc. AE
4.8 g 1 times / day steady, oral
Recommended
Dose: 4.8 g, 1 times / day
Route: oral
Route: steady
Dose: 4.8 g, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​Drug as victim
PubMed

PubMed

TitleDatePubMed
Is it Crohn's disease? A severe systemic granulomatous reaction to sulfasalazine in patient with rheumatoid arthritis.
2001
TNF-alpha induced endothelial MAdCAM-1 expression is regulated by exogenous, not endogenous nitric oxide.
2001
Tolerability of aminosalicylates in inflammatory bowel disease.
2001
A 10-year survey of inflammatory bowel diseases-drug therapy, costs and adverse reactions.
2001 Apr
[Hepatotoxicity of medications].
2001 Apr 14
[The new experimental ulcerative colitis model in rats induced by subserosal injection of acetic acid].
2001 Aug
Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis.
2001 Aug
Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine.
2001 Aug
The expression of IL-12 p40 and its homologue, Epstein-Barr virus-induced gene 3, in inflammatory bowel disease.
2001 Aug
Inflammatory pseudotumor of the liver as the first manifestation of Crohn's disease.
2001 Aug
Adult fibrosing colonopathy associated with mesalazine treatment.
2001 Aug
[Metastatic Crohn's disease in childhood].
2001 Aug
Glucocorticoids and IL-10, but not 6-MP, 5-ASA or sulfasalazine block endothelial expression of MAdCAM-1: implications for inflammatory bowel disease therapy.
2001 Aug
Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy.
2001 Aug
Effects of chondroitin sulfate on colitis induced by dextran sulfate sodium in rats.
2001 Feb
5-Aminosalicylic acid protection against oxidative damage to synaptosomal membranes by alkoxyl radicals in vitro.
2001 Jan
[Hypersensitivity to mesalazine after severe allergic reaction to sulfasalazine].
2001 Jan
[Therapeutic principles for chronic inflammatory bowel disease].
2001 Jan 1
Recurrent atypical myxoid fibroepithelial polyp associated with vulvar Crohn's disease.
2001 Jul
Comparison of 5-amino salicylic acid plus glucocorticosteroid with metronidazole and ciprofloxacin in patients with active ulcerative colitis.
2001 Jul
Mesalamine-induced unilateral eosinophilic pneumonia.
2001 Jul
Oral balsalazide (Colazal) for ulcerative colitis.
2001 Jul 23
[A case of successful mesalazine enema for rectal cavitating ulcer of Crohn's disease].
2001 Jun
Probiotics (Br J Surg 2001; 88: 161-2).
2001 Jun
In vitro effects of E3040, a dual inhibitor of 5-lipoxygenase and thromboxane A(2) synthetase, on eicosanoid production.
2001 Jun 22
5-Aminosalicylates in inflammatory bowel disease: choosing the right dose.
2001 Jun-Jul
T-large granular lymphocyte leukemia accompanied by an increase of natural killer cells (CD3-) and associated with ulcerative colitis and autoimmune hepatitis.
2001 Mar
Treatment responses in collagenous colitis.
2001 Mar
Impact of different therapeutic regimens on the outcome of patients with Crohn's disease of the upper gastrointestinal tract.
2001 May
Inflammatory bowel disease and pregnancy.
2001 May
Crohn's disease of the esophagus: clinical features and outcomes.
2001 May
Familial microscopic colitis.
2001 May
Conventional treatment of Crohn's disease: objectives and outcomes.
2001 May
Determination of 5-aminosalicylic acid related impurities by micellar electrokinetic chromatography with an ion-pair reagent.
2001 May 4
Salvage external beam radiotherapy for clinical failure after cryosurgery for prostate cancer.
2001 Nov 1
Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug.
2001 Oct
Recent advances in the treatment of the seronegative spondyloarthropathies.
2001 Oct
Review article: balsalazide therapy in ulcerative colitis.
2001 Oct
Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study.
2001 Oct
Mesalamine induces manganese superoxide dismutase in rat intestinal epithelial cell lines and in vivo.
2001 Oct
[Collagenous colitis. A study of 11 cases].
2001 Sep
Headache during mesalamine therapy: a case report of mesalamine-induced pseudotumor cerebri.
2001 Sep
The hair of the dog.
2001 Sep
[Generalized pustulous psoriasis: A novel extraintestinal manifestation of Crohn's disease?].
2001 Sep
Review article: current therapeutic options for radiation proctopathy.
2001 Sep
NO-mesalamine protects colonic epithelial cells against apoptotic damage induced by proinflammatory cytokines.
2001 Sep
Drug points: Hypersensitivity reaction to balsalazide.
2001 Sep 1
[Conservative therapy of severe ulcerative colitis. More effective than internists believe!].
2001 Sep 13
Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial.
2001 Sep 22
5-Aminosalicylate stimulates phospholipase D activity in macrophages.
2001 Sep 28
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: can also be used rectally
Usual Adult Dose for Ulcerative Colitis - Active
Route of Administration: Oral
Treatment of both HT-29 wild-type, dominant-negative PPARg and empty vector cells HT-29 cells with Mesalamine (30 mM) for 48 h increased the activity of PPARg
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:55:08 UTC 2021
Edited
by admin
on Fri Jun 25 20:55:08 UTC 2021
Record UNII
4Q81I59GXC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MESALAMINE
HSDB   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF  
USAN  
Official Name English
MESALAMINE [VANDF]
Common Name English
MESALAMINE [HSDB]
Common Name English
MESALAZINE [EP MONOGRAPH]
Common Name English
MESALAZINE [INN]
Common Name English
MESALAMINE [USP MONOGRAPH]
Common Name English
FISALAMINE
Common Name English
ASACOL
Brand Name English
MESALAZINE [JAN]
Common Name English
ROWASA
Brand Name English
MESALAMINE [MI]
Common Name English
MESALAZINE [EP]
Common Name English
5-AMINOSALICYLIC ACID
Systematic Name English
APRISO
Brand Name English
NSC-38877
Code English
5-AMINO-2-HYDROXYBENZOIC ACID
Systematic Name English
BENZOIC ACID, 5-AMINO-2-HYDROXY-
Common Name English
PENTASA
Brand Name English
MESALAZINE [WHO-DD]
Common Name English
MESALAZINE [MART.]
Common Name English
SFROWASA
Brand Name English
MESALAMINE [USAN]
Common Name English
LIALDA
Brand Name English
MAX-002
Code English
MESALAZINE
EP   INN   JAN   MART.   WHO-DD  
INN  
Official Name English
MESALAMINE [ORANGE BOOK]
Common Name English
MESALAMINE [USP-RS]
Common Name English
CANASA
Brand Name English
IIALDA
Brand Name English
M-AMINOSALICYLIC ACID
Systematic Name English
Classification Tree Code System Code
WHO-VATC QA07EC02
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
FDA ORPHAN DRUG 253607
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
NDF-RT N0000005760
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
LIVERTOX 605
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
NDF-RT N0000005760
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
FDA ORPHAN DRUG 275909
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
FDA ORPHAN DRUG 298109
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
NDF-RT N0000005760
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
NDF-RT N0000005760
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
NDF-RT N0000175781
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
NCI_THESAURUS C257
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
WHO-ATC A07EC02
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C29249
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
LACTMED
Mesalamine
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
MESH
D019804
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
CAS
89-57-6
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
ECHA (EC/EINECS)
201-919-1
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
DRUG CENTRAL
1710
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
FDA UNII
4Q81I59GXC
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
HSDB
7512
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
PUBCHEM
4075
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
EVMPD
SUB08782MIG
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
EPA CompTox
89-57-6
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
IUPHAR
2700
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
RXCUI
52582
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY RxNorm
WIKIPEDIA
MESALAZINE
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
DRUG BANK
DB00244
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
ChEMBL
CHEMBL704
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
INN
5444
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY
USP_CATALOG
1392705
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY USP-RS
MERCK INDEX
M7244
Created by admin on Fri Jun 25 20:55:08 UTC 2021 , Edited by admin on Fri Jun 25 20:55:08 UTC 2021
PRIMARY Merck Index
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
PARENT -> METABOLITE ACTIVE
Inhibite the Hb-catalyzed peroxidative reaction
PRODRUG -> METABOLITE ACTIVE
PRODRUG -> METABOLITE ACTIVE
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
Correction factors: for the calculation of contents, multiply the peak areas by 0.6
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
USP
IMPURITY -> PARENT
Correction factors: for the calculation of contents, multiply the peak areas by 1.3
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
USP
IMPURITY -> PARENT
Correction factors: for the calculation of contents, multiply the peak areas by 2.0
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
USP
IMPURITY -> PARENT
Correction factors: for the calculation of contents, multiply the peak areas by 1.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
Correction factors: for the calculation of contents, multiply the peak areas by 1.3
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
Correction factors: for the calculation of contents, multiply the peak areas by 1.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
Correction factors: for the calculation of contents, multiply the peak areas by 4.5
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
Correction factors: for the calculation of contents, multiply the peak areas by 1.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
Correction factors: for the calculation of contents, multiply the peak areas by 0.6
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC Elimination
PHARMACOKINETIC